Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

The transcription factor NFAT5 limits infection-induced type I interferon responses.

Huerga Encabo H, Traveset L, Argilaguet J, Angulo A, Nistal-Villán E, Jaiswal R, Escalante CR, Gekas C, Meyerhans A, Aramburu J, López-Rodríguez C.

J Exp Med. 2020 Mar 2;217(3). pii: e20190449. doi: 10.1084/jem.20190449.

PMID:
31816635
2.

Repurposing the yellow fever vaccine for intratumoral immunotherapy.

Aznar MA, Molina C, Teijeira A, Rodriguez I, Azpilikueta A, Garasa S, Sanchez-Paulete AR, Cordeiro L, Etxeberria I, Alvarez M, Rius-Rocabert S, Nistal-Villan E, Berraondo P, Melero I.

EMBO Mol Med. 2019 Nov 19:e10375. doi: 10.15252/emmm.201910375. [Epub ahead of print]

3.

A Digital Method to Quantify Type I Interferon.

Rius-Rocabert S, Presa JL, Esteban-Rubio S, Ayuso-Sacido A, Nistal-Villan E.

J Interferon Cytokine Res. 2019 Nov;39(11):711-719. doi: 10.1089/jir.2019.0046. Epub 2019 Jul 3.

PMID:
31268382
4.

Oncolytic bacteria: past, present and future.

Rius-Rocabert S, Llinares Pinel F, Pozuelo MJ, García A, Nistal-Villan E.

FEMS Microbiol Lett. 2019 Jun 1;366(12). pii: fnz136. doi: 10.1093/femsle/fnz136.

PMID:
31226708
5.

TMEM173 Alternative Spliced Isoforms Modulate Viral Replication through the STING Pathway.

Rodríguez-García E, Olagüe C, Ríus-Rocabert S, Ferrero R, Llorens C, Larrea E, Fortes P, Prieto J, González-Aseguinolaza G, Nistal-Villan E.

Immunohorizons. 2018 Dec 11;2(11):363-376. doi: 10.4049/immunohorizons.1800068.

PMID:
31026807
6.

Characterization of Ovine A3Z1 Restriction Properties against Small Ruminant Lentiviruses (SRLVs).

de Pablo-Maiso L, Glaria I, Crespo H, Nistal-Villán E, Andrésdóttir V, de Andrés D, Amorena B, Reina R.

Viruses. 2017 Nov 17;9(11). pii: E345. doi: 10.3390/v9110345.

7.

miR-146a targets c-met and abolishes colorectal cancer liver metastasis.

Bleau AM, Redrado M, Nistal-Villan E, Villalba M, Exposito F, Redin E, de Aberasturi AL, Larzabal L, Freire J, Gomez-Roman J, Calvo A.

Cancer Lett. 2018 Feb 1;414:257-267. doi: 10.1016/j.canlet.2017.11.008. Epub 2017 Nov 11.

PMID:
29133238
8.

Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function.

Vasquez M, Fioravanti J, Aranda F, Paredes V, Gomar C, Ardaiz N, Fernandez-Ruiz V, Méndez M, Nistal-Villan E, Larrea E, Gao Q, Gonzalez-Aseguinolaza G, Prieto J, Berraondo P.

Oncoimmunology. 2016 Jun 29;5(8):e1196309. doi: 10.1080/2162402X.2016.1196309. eCollection 2016 Aug.

9.

Mitochondrial respiratory-chain adaptations in macrophages contribute to antibacterial host defense.

Garaude J, Acín-Pérez R, Martínez-Cano S, Enamorado M, Ugolini M, Nistal-Villán E, Hervás-Stubbs S, Pelegrín P, Sander LE, Enríquez JA, Sancho D.

Nat Immunol. 2016 Sep;17(9):1037-1045. doi: 10.1038/ni.3509. Epub 2016 Jun 27.

10.

A Versatile Vector for In Vivo Monitoring of Type I Interferon Induction and Signaling.

Nistal-Villan E, Poutou J, Rodríguez-Garcia E, Buñuales M, Carte-Abad B, Prieto J, Gonzalez-Aseguinolaza G, Hernandez-Alcoceba R, Larrea E.

PLoS One. 2016 Mar 23;11(3):e0152031. doi: 10.1371/journal.pone.0152031. eCollection 2016.

11.

Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.

Nistal-Villan E, Bunuales M, Poutou J, Gonzalez-Aparicio M, Bravo-Perez C, Quetglas JI, Carte B, Gonzalez-Aseguinolaza G, Prieto J, Larrea E, Hernandez-Alcoceba R.

Mol Cancer. 2015 Dec 16;14:210. doi: 10.1186/s12943-015-0479-x.

12.

A RIG-I 2CARD-MAVS200 Chimeric Protein Reconstitutes IFN-β Induction and Antiviral Response in Models Deficient in Type I IFN Response.

Nistal-Villán E, Rodríguez-García E, Di Scala M, Ferrero-Laborda R, Olagüe C, Vales Á, Carte-Abad B, Crespo I, García-Sastre A, Prieto J, Larrea E, González-Aseguinolaza G.

J Innate Immun. 2015;7(5):466-81. doi: 10.1159/000375262. Epub 2015 May 5.

13.

The inhibitor of differentiation isoform Id1b, generated by alternative splicing, maintains cell quiescence and confers self-renewal and cancer stem cell-like properties.

Manrique I, Nguewa P, Bleau AM, Nistal-Villan E, Lopez I, Villalba M, Gil-Bazo I, Calvo A.

Cancer Lett. 2015 Jan 28;356(2 Pt B):899-909. doi: 10.1016/j.canlet.2014.10.035. Epub 2014 Nov 6.

PMID:
25449776
14.

New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations.

Bleau AM, Freire J, Pajares MJ, Zudaire I, Anton I, Nistal-Villán E, Redrado M, Zandueta CN, Garmendia I, Ajona D, Blanco D, Pio R, Lecanda F, Calvo A, Montuenga LM.

Int J Cancer. 2014 Dec 1;135(11):2516-27. doi: 10.1002/ijc.28574. Epub 2014 Jan 28.

15.

T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.

Martinez-Forero I, Azpilikueta A, Bolaños-Mateo E, Nistal-Villan E, Palazon A, Teijeira A, Perez-Chacon G, Morales-Kastresana A, Murillo O, Jure-Kunkel M, Zapata JM, Melero I.

J Immunol. 2013 Jun 15;190(12):6694-706. doi: 10.4049/jimmunol.1203010. Epub 2013 May 20.

16.

Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein.

Rajsbaum R, Albrecht RA, Wang MK, Maharaj NP, Versteeg GA, Nistal-Villán E, García-Sastre A, Gack MU.

PLoS Pathog. 2012;8(11):e1003059. doi: 10.1371/journal.ppat.1003059. Epub 2012 Nov 29.

17.

Structure and dynamics of the second CARD of human RIG-I provide mechanistic insights into regulation of RIG-I activation.

Ferrage F, Dutta K, Nistal-Villán E, Patel JR, Sánchez-Aparicio MT, De Ioannes P, Buku A, Aseguinolaza GG, García-Sastre A, Aggarwal AK.

Structure. 2012 Dec 5;20(12):2048-61. doi: 10.1016/j.str.2012.09.003. Epub 2012 Oct 11.

18.

A common polymorphism in the caspase recruitment domain of RIG-I modifies the innate immune response of human dendritic cells.

Hu J, Nistal-Villán E, Voho A, Ganee A, Kumar M, Ding Y, García-Sastre A, Wetmur JG.

J Immunol. 2010 Jul 1;185(1):424-32. doi: 10.4049/jimmunol.0903291. Epub 2010 May 28.

19.

Negative role of RIG-I serine 8 phosphorylation in the regulation of interferon-beta production.

Nistal-Villán E, Gack MU, Martínez-Delgado G, Maharaj NP, Inn KS, Yang H, Wang R, Aggarwal AK, Jung JU, García-Sastre A.

J Biol Chem. 2010 Jun 25;285(26):20252-61. doi: 10.1074/jbc.M109.089912. Epub 2010 Apr 20.

20.

Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines.

Manicassamy B, Medina RA, Hai R, Tsibane T, Stertz S, Nistal-Villán E, Palese P, Basler CF, García-Sastre A.

PLoS Pathog. 2010 Jan 29;6(1):e1000745. doi: 10.1371/journal.ppat.1000745.

21.

Phosphorylation-mediated negative regulation of RIG-I antiviral activity.

Gack MU, Nistal-Villán E, Inn KS, García-Sastre A, Jung JU.

J Virol. 2010 Apr;84(7):3220-9. doi: 10.1128/JVI.02241-09. Epub 2010 Jan 13.

22.

New prospects for the rational design of antivirals.

Nistal-Villán E, García-Sastre A.

Nat Med. 2009 Nov;15(11):1253-4. doi: 10.1038/nm1109-1253. No abstract available.

23.

Structure of IRF-3 bound to the PRDIII-I regulatory element of the human interferon-beta enhancer.

Escalante CR, Nistal-Villán E, Shen L, García-Sastre A, Aggarwal AK.

Mol Cell. 2007 Jun 8;26(5):703-16.

24.

Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells.

Efferson CL, Tsuda N, Kawano K, Nistal-Villán E, Sellappan S, Yu D, Murray JL, García-Sastre A, Ioannides CG.

J Virol. 2006 Jan;80(1):383-94.

25.

Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina).

Baskin CR, García-Sastre A, Tumpey TM, Bielefeldt-Ohmann H, Carter VS, Nistal-Villán E, Katze MG.

J Virol. 2004 Oct;78(19):10420-32.

Supplemental Content

Loading ...
Support Center